Sonoma Pharmaceuticals (SNOA) Return on Invested Capital (2016 - 2026)

Sonoma Pharmaceuticals' Return on Invested Capital history runs 10 years deep, the most recent figure standing at 0.05% for Q1 2026.

• On a quarterly basis, Return on Invested Capital rose 2.0% year-over-year to 0.05% in Q1 2026; TTM through Mar 2026 was 0.05%, a 2.0% increase from a year earlier, with the FY2026 full-year figure at 0.1%, up 6.0% from the prior year.
• Return on Invested Capital advanced to 0.05% in Q1 2026 per SNOA's latest filing, from 0.07% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.02% in Q1 2022 and bottomed at 0.09% in Q2 2025.
• The 5-year median for Return on Invested Capital is 0.05% (2026), against an average of 0.05%.
• Across the five-year window, Return on Invested Capital gained 3 bps in 2022 and decreased 3 bps in 2023, its largest moves.
• Year by year, Return on Invested Capital stood at 0.04% in 2022, then fell by 13 bps to 0.05% in 2023, then tumbled by 49 bps to 0.07% in 2024, then gained by 8 bps to 0.07% in 2025, then gained by 16 bps to 0.05% in 2026.
• Per Business Quant, the three latest SNOA Return on Invested Capital figures stand at 0.05% (Q1 2026), 0.07% (Q4 2025), and 0.07% (Q3 2025).